Home > Insider Trading > Filing (0001209191-15-042578)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1267565	Collegium Pharmaceutical Inc	COLL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1277503	Yasunori Kaneko	525 University Avenue, Suite 610 Palo Alto CA 94301	No	No	Yes	No
1419187	Skyline Venture Partners V Lp	525 University Avenue, Suite 610 Palo Alto CA 94301	No	No	Yes	No
1434887	Skyline Venture Management V, Llc	525 University Avenue, Suite 610 Palo Alto CA 94301	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-05-12	1,552,795	$0.00	1,552,795	No	4	C	Indirect	see footnote
Common Stock	Acquisiton	2015-05-12	382,323	$0.00	1,935,118	No	4	C	Indirect	see footnote
Common Stock	Acquisiton	2015-05-12	864,798	$0.00	2,799,916	No	4	C	Indirect	see footnote
Common Stock	Acquisiton	2015-05-12	150,000	$12.00	2,949,916	No	4	P	Indirect	see footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	see footnote
No	4	C	Indirect	see footnote
No	4	C	Indirect	see footnote
No	4	P	Indirect	see footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2015-05-12	10,714,286	$0.00	1,552,795	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2015-05-12	2,638,030	$0.00	382,323	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2015-05-12	5,881,724	$0.00	864,798	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

All series of Convertible Preferred Stock automatically converted into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis immediately prior to the closing of the initial public offering and had no expiration date.
Reflects the conversion of preferred stock into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis which became effective on May 12, 2015.
The shares are held by Skyline Venture Partners V, L.P. The general partner of Skyline Venture Partners V, L.P. is Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management, LLC and disclaim beneficial ownership of all the shares held by Skyline Venture Partners V, L.P. except to the extent of their proportionate pecuniary interest therein. Dr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports.